NRx’s HOPE Therapeutics Prepares First Robotic TMS Deployment in Florida

Key Points

• NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics.
• HOPE said it will become the first interventional psychiatry network to use the Zeta TMS Robotic System.
• The system uses AI-guided software to track patient movement and adjust the TMS coil in real time with submillimeter precision.
• The deployment supports NRx’s FDA-cleared Phase 2/3 SPARC-TMS study, which is evaluating NRX-101 with robotic TMS.
• NRx was selected by DARPA as prime contractor for SPARC-TMS, subject to completion of contracting.

NRx Pharmaceuticals (Nasdaq: NRXP) announced that its HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS system at HOPE clinics in Florida.

HOPE’s clinical team is completing training at Zeta Surgical’s headquarters in Boston before the system moves into clinical use. The company said HOPE will be the first interventional psychiatry network to deploy the Zeta TMS Robotic System.

AI-Guided Robotic TMS Tracks Patient Movement During Treatment

TMS is a noninvasive treatment that uses magnetic pulses to stimulate selected areas of the brain. It is used primarily in treatment-resistant depression, a condition affecting about one-third of people with major depressive disorder, according to the company.

The Zeta TMS Robotic System uses AI-driven software to track a patient’s head during treatment and automatically adjust the placement of the TMS coil. The system is designed to maintain submillimeter targeting precision even if a patient moves.

The robotic system places the TMS coil on a robotic arm and continuously refocuses treatment energy on the MRI-guided brain target. NRx said the technology may improve the accuracy and repeatability of treatment delivery.

Zeta System Builds on HOPE’s Earlier Navigation Rollout

HOPE began treating patients with Zeta Surgical’s TMS Navigation System in June 2026. The navigation platform uses AI-driven image guidance to show clinicians the position of the TMS coil relative to a patient’s MRI-guided treatment target.

Zeta Surgical received FDA 510(k) clearance for the robotic TMS system in July 2026. The clearance permits marketing of the device for its cleared use, but it does not establish that robotic TMS produces better treatment results than other TMS approaches.

NRx has not released clinical outcome data from the planned use of the robotic system in its Florida network.

Robotic TMS Supports SPARC-TMS Trial of NRX-101

The deployment will support SPARC-TMS, NRx’s FDA-cleared Phase 2/3 clinical trial evaluating NRX-101 in combination with robotic TMS.

The planned study is expected to take place at a major U.S. academic teaching hospital, multiple HOPE Therapeutics clinics, and two military treatment facilities.

NRx said DARPA selected the company as prime contractor for the SPARC-TMS program, although completion of the related contract remains pending.

Next Steps Include Florida Launch and Clinical Trial Execution

The Florida deployment is an operating milestone as NRx expands HOPE’s interventional psychiatry network and advances its robotic TMS clinical program.

Key next steps include completion of clinical training, installation of the robotic systems, finalization of DARPA contracting, SPARC-TMS trial enrollment, and future data updates.

NRX-101 remains investigational. The company will need to demonstrate safety and clinical benefit in its trial before the drug could receive regulatory approval